Rachael Natrajan

Team Leader

Institute of Cancer Research
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Genomic defects caused by truncating mutations or deletions in the Retinoblastoma tumor suppressor gene ( RB1 ) are frequently observed in many cancer types leading to dysregulation of the RB pathway. Here, we propose an integrative proteogenomic approach that predicts cancers with dysregulation in the RB pathway. A subset of these cancers, which we term as “RBness,” lack RB1 genomic defects and yet phenocopy the transcriptional profile of RB1 -defective cancers. We report RBness as a pan-cancer phenomenon, associated with patient outcome and chemotherapy response in multiple cancer types, and predictive of CDK4/6 inhibitor response in estrogen-positive breast cancer. Using RNA interference and a CRISPR-Cas9 screen in isogenic models, we find that RBness cancers also phenocopy synthetic lethal vulnerabilities of cells with RB1 genomic defects. In summary, our findings suggest that dysregulation of the RB pathway in cancers lacking RB1 genomic defects provides a molecular rationale for how these cancers could be treated.

Year:

2025

Understanding tumour evolution is key to overcoming resistance to CDK4/6 inhibitors (CDK4/6i) in oestrogen receptor positive breast cancer. While genetic changes contribute, many patients lack identifiable mutations, suggestive of non-genetic epigenetic reprogramming and transcriptional plasticity. Here, we integrate expressed barcode lineage tracing, single-cell and bulk profiling, together with mathematical modelling, to study the evolution of resistance to the clinically approved CDK4/6i; Abemaciclib and Palbociclib. Our findings show that the evolutionary path to resistance to CDK4/6i is dependent on both the specific drug and the cancer cell model and can be driven by heritable epigenetic changes, independent of other acquired genetic driver alterations. We identify epigenetically driven transcriptional cell states that pre-exist as minority sub-populations in parental cells that become enriched in CDK4/6i resistant cells and are characterised by increased enhancer accessibility despite resistant cells showing overall reduced global accessibility. These transcriptional states show open chromatin in parental cells, suggestive of the presence of pre-existing epigenetically ‘primed’ cells. Finally, we generate and validate a core set of genes predictive of neoadjuvant endocrine + CDK4/6i response. Functional genomic assessment of candidate genes from this signature highlights potential collateral vulnerabilities in resistant cells. Overall, our study highlights the functional role of epigenetic adaptation in driving CDK4/6i resistance.

Year:

2025

The PI3K/AKT/mTOR pathway is central to cell metabolism and growth. However, pharmacological inhibition of the pathway is not uniformly effective across cancer types, or even within a single cancer model. In this study, we leverage oblique plane microscopy of triple negative breast cancer organoids, as well as lineage tracing to uncover a source of heterogeneity. Non-genetic resistance to AKT inhibition is associated with basal cell features of normal breast epithelium and the master transcription factor of basal cell state, ΔNp63α, is sufficient to confer resistance. Cells can transition between states within four weeks and therefore, AKT inhibition only delays tumour growth, with tumours rich in KRT14+ cells resulting. Thus, under selection, triple negative breast cancer exploits a repertoire of cell states inherent to the breast.

Year:

2025

Background Invasive Lobular Carcinoma (ILC) is a morphologically distinct breast cancer subtype that represents up to 15% of all breast cancers. Compared to Invasive Breast Carcinoma of No Special Type (IBC-NST), ILCs exhibit poorer long-term outcome and a unique pattern of metastasis. Despite these differences, the systematic discovery of robust prognostic biomarkers and therapeutically actionable molecular pathways in ILC remains limited. Methods Pathway-centric multivariable models using statistical machine learning were developed and tested in seven retrospective clinico-genomic cohorts ( n = 996). Further external validation was performed using a new RNA-Seq clinical cohort of aggressive ILCs ( n = 48). Results and conclusions mRNA dysregulation scores of 25 pathways were strongly prognostic in ILC (FDR-adjusted P < 0.05). Of these, three pathways including Cell-cell communication, Innate immune system and Smooth muscle contraction were also independent predictors of chemotherapy response. To aggregate these findings, a multivariable machine learning predictor called PSILC was developed and successfully validated for predicting overall and metastasis-free survival in ILC. Integration of PSILC with CRISPR-Cas9 screening data from breast cancer cell lines revealed 16 candidate therapeutic targets that were synthetic lethal with high-risk ILCs. This study provides interpretable prognostic and predictive biomarkers of ILC which could serve as the starting points for targeted drug discovery for this disease.

Year:

2024

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by extensive intratumoral heterogeneity, high metastasis, and chemoresistance, leading to poor clinical outcomes. Despite progress, the mechanistic basis of these aggressive behaviors remains poorly understood. Using single-cell and spatial transcriptome analysis, here we discovered basal epithelial subpopulations located within the stroma that exhibit chemoresistance characteristics. The subpopulations are defined by distinct signature genes that show a frequent gain in copy number and exhibit an activated epithelial-to-mesenchymal transition program. A subset of these genes can accurately predict chemotherapy response and are associated with poor prognosis. Interestingly, among these genes, elevated ITGB1 participates in enhancing intercellular signaling while ACTN1 confers a survival advantage to foster chemoresistance. Furthermore, by subjecting the transcriptional signatures to drug repurposing analysis, we find that chemoresistant tumors may benefit from distinct inhibitors in treatment-naive versus post-NAC patients. These findings shed light on the mechanistic basis of chemoresistance while providing the best-in-class biomarker to predict chemotherapy response and alternate therapeutic avenues for improved management of TNBC patients resistant to chemotherapy.

Year:

2024

Year:

2023

Year:

2023

Collaborators (17)

Christopher Lord

Professor of Cancer Genomics

Institute of Cancer Research

UNITED KINGDOM
View details

Clare Isacke

Professor of Molecular Cell Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Fabian Fröhlich

Group Leader

The Francis Crick Institute

UNITED KINGDOM
View details

Andrea Serio

Group Leader (Seconded)

King’s College London

UNITED KINGDOM
View details

LISA ABEGGLEN

Research Associate Professor

University of Utah

UNITED STATES
View details

Rebecca Lee

The University of Manchester

UNITED KINGDOM
View details

J Michael Dixon

Professor

University of Edinburgh

UNITED KINGDOM
View details

Morag Park

McGill University

CANADA
View details

Arun Mariappan

Assistant Professor

University of Southern Denmark

DENMARK
View details

Trevor A Graham

Director

Institute of Cancer Research

UNITED KINGDOM
View details

James MacRae

Head of metabolomics

The Francis Crick Institute

UNITED KINGDOM
View details

Vijay Tiwari

The Queen's University Belfast

UNITED KINGDOM
View details

Andrew Tutt

Professor of Clinical Oncology

Institute of Cancer Research

UNITED KINGDOM
View details

Chris Dunsby

-

UNITED KINGDOM
View details

James Briscoe

The Francis Crick Institute

UNITED KINGDOM
View details

Joshua Schiffman

Professor

University of Utah Health

UNITED STATES
View details

Erik Sahai

The Francis Crick Institute

UNITED KINGDOM
View details